FDA Pulmonary Division acting director
Executive Summary
Badrul Chowdhury, MD/PhD, appointed acting director of FDA's CDER Division of Pulmonary & Allergy Drug Products. Chowdhury, a team leader in the division for three years and a member of the Clarinex review team, succeeds Robert Meyer, MD, who became Office of Drug Evaluation II director in June (1"The Pink Sheet" June 3, p. 9)...
You may also be interested in...
FDA pulmonary division director
Badrul Chowdhury, MD/PhD, named permanent director of CDER's Division of Pulmonary & Allergy Drug Products. He has served as acting director since July 2002 following the promotion of Robert Meyer, MD, to Office of Drug Evaluation II director (1"The Pink Sheet" July 8, 2002, In Brief)...
ODE II Director Is Pulmonary & Allergy Division Chief Meyer
Pulmonary & Allergy Drug Products Division Director Robert Meyer, MD, will become Office of Drug Evaluation II director effective June 16
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.